

Andrea Velardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11941646/publications.pdf>

Version: 2024-02-01

135
papers

16,540
citations

31902

53
h-index

18606

119
g-index

139
all docs

139
docs citations

139
times ranked

11054
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants. <i>Science</i> , 2002, 295, 2097-2100.	6.0	3,071
2	Treatment of High-Risk Acute Leukemia with T-Cell-Depleted Stem Cells from Related Donors with One Fully Mismatched HLA Haplotype. <i>New England Journal of Medicine</i> , 1998, 339, 1186-1193.	13.9	1,141
3	Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. <i>Blood</i> , 2011, 117, 3921-3928.	0.6	940
4	Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 1999, 94, 333-339.	0.6	884
5	Full Haplotype-Mismatched Hematopoietic Stem-Cell Transplantation: A Phase II Study in Patients With Acute Leukemia at High Risk of Relapse. <i>Journal of Clinical Oncology</i> , 2005, 23, 3447-3454.	0.8	677
6	Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.. <i>Blood</i> , 2007, 110, 433-440.	0.6	550
7	Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. <i>Blood</i> , 2003, 102, 814-819.	0.6	515
8	Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. <i>Blood</i> , 2002, 100, 1935-1947.	0.6	449
9	Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. <i>Blood</i> , 2009, 114, 2667-2677.	0.6	363
10	HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. <i>Blood</i> , 2014, 124, 638-644.	0.6	358
11	Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. <i>Blood</i> , 2002, 100, 3825-3827.	0.6	356
12	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. <i>Blood</i> , 2011, 118, 3273-3279.	0.6	356
13	Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. <i>Blood</i> , 2005, 106, 4397-4406.	0.6	343
14	NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. <i>Journal of Clinical Investigation</i> , 2009, 119, 1251-1263.	3.9	313
15	Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. <i>Lancet Oncology</i> , The, 2012, 13, 366-374.	5.1	289
16	Genetic PTX3 Deficiency and Aspergillosis in Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2014, 370, 421-432.	13.9	265
17	Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. <i>Blood</i> , 2010, 116, 5394-5402.	0.6	259
18	The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 876-884.	2.0	241

#	ARTICLE	IF	CITATIONS
19	A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. <i>Blood</i> , 2003, 102, 3807-3814.	0.6	220
20	Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. <i>Blood</i> , 2008, 112, 2990-2995.	0.6	217
21	NK cells: a lesson from mismatched hematopoietic transplantation. <i>Trends in Immunology</i> , 2002, 23, 438-444.	2.9	191
22	Thymosin $\hat{\pm}$ 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. <i>Blood</i> , 2004, 103, 4232-4239.	0.6	189
23	Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. <i>Blood</i> , 2006, 107, 2846-2854.	0.6	183
24	Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. <i>Blood</i> , 2001, 97, 2514-2521.	0.6	182
25	Thymosin $\hat{\pm}$ 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. <i>Blood</i> , 2006, 108, 2265-2274.	0.6	172
26	Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. <i>Immunological Reviews</i> , 2006, 214, 202-218.	2.8	149
27	HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 3996-4003.	0.6	146
28	Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. <i>Current Opinion in Immunology</i> , 2009, 21, 525-530.	2.4	137
29	NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 84-90.	0.6	134
30	Increased Ratio of CD31 + /CD42 $\hat{\sim}$ Microparticles to Endothelial Progenitors as a Novel Marker of Atherosclerosis in Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2530-2535.	1.1	128
31	Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. <i>Haematologica</i> , 2016, 101, 626-633.	1.7	128
32	Dendritic Cells Pulsed with Fungal RNA Induce Protective Immunity to <i>Candida albicans</i> in Hematopoietic Transplantation. <i>Journal of Immunology</i> , 2002, 168, 2904-2913.	0.4	126
33	TLR3 essentially promotes protective class II-restricted memory CD8+ T-cell responses to <i>Aspergillus fumigatus</i> in hematopoietic transplanted patients. <i>Blood</i> , 2012, 119, 967-977.	0.6	117
34	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1914-1921.	3.2	110
35	Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. <i>Blood</i> , 2015, 125, 3173-3182.	0.6	108
36	Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. <i>Current Opinion in Immunology</i> , 2005, 17, 211-217.	2.4	106

#	ARTICLE	IF	CITATIONS
37	Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. <i>Blood</i> , 2008, 112, 708-710.	0.6	105
38	Cellular therapy: exploiting NK cell alloreactivity in transplantation. <i>Current Opinion in Hematology</i> , 2001, 8, 355-359.	1.2	80
39	Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. <i>Current Opinion in Oncology</i> , 2007, 19, 142-147.	1.1	78
40	Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. <i>Atherosclerosis</i> , 2008, 197, 757-767.	0.4	76
41	Role of KIRs and KIR ligands in hematopoietic transplantation. <i>Current Opinion in Immunology</i> , 2008, 20, 581-587.	2.4	75
42	“Designed” grafts for HLA-haploidentical stem cell transplantation. <i>Blood</i> , 2014, 123, 967-973.	0.6	71
43	Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists. <i>Blood</i> , 2001, 97, 1483-1490.	0.6	70
44	T cells expressing chimeric antigen receptor promote immune tolerance. <i>JCI Insight</i> , 2017, 2, .	2.3	68
45	Involvement of CD44 variant isoforms in hyaluronate adhesion by human activated T cells. <i>European Journal of Immunology</i> , 1995, 25, 2932-2939.	1.6	67
46	Protection of Killer Antidiotypic Antibodies against Early Invasive Aspergillosis in a Murine Model of Allogeneic T-Cell-Depleted Bone Marrow Transplantation. <i>Infection and Immunity</i> , 2002, 70, 2375-2382.	1.0	67
47	Transplants across human leukocyte antigen barriers. <i>Seminars in Hematology</i> , 2002, 39, 48-56.	1.8	66
48	Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1197-1203.	2.0	63
49	Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. <i>Nature Communications</i> , 2017, 8, 15068.	5.8	63
50	Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 76-83.	0.6	61
51	Natural Killer Cell Alloreactivity for Leukemia Therapy. <i>Journal of Immunotherapy</i> , 2005, 28, 175-182.	1.2	58
52	Noncanonical Fungal Autophagy Inhibits Inflammation in Response to IFN- γ via DAPK1. <i>Cell Host and Microbe</i> , 2016, 20, 744-757.	5.1	56
53	Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. <i>British Journal of Haematology</i> , 2001, 114, 11-24.	1.2	54
54	Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation. <i>Blood</i> , 2016, 128, 2616-2623.	0.6	54

#	ARTICLE	IF	CITATIONS
55	Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. <i>Current Opinion in Hematology</i> , 2012, 19, 319-323.	1.2	51
56	Genetically-Determined Hyperfunction of the S100B/RAGE Axis Is a Risk Factor for Aspergillosis in Stem Cell Transplant Recipients. <i>PLoS ONE</i> , 2011, 6, e27962.	1.1	47
57	Natural killer cell alloreactivity 10 years later. <i>Current Opinion in Hematology</i> , 2012, 19, 421-426.	1.2	43
58	The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. <i>Transplant Immunology</i> , 2005, 14, 203-206.	0.6	42
59	Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 459-466.	0.7	40
60	Jack of all trades: thymosin $\hat{\pm}1$ and its pleiotropy. <i>Annals of the New York Academy of Sciences</i> , 2012, 1269, 1-6.	1.8	40
61	Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. <i>Seminars in Cancer Biology</i> , 2006, 16, 404-411.	4.3	39
62	Prospects for dendritic cell vaccination against fungal infections in hematopoietic transplantation. <i>Blood Cells, Molecules, and Diseases</i> , 2004, 33, 248-255.	0.6	38
63	Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation. <i>Blood Cells, Molecules, and Diseases</i> , 2004, 33, 216-221.	0.6	34
64	Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1199-1208.	2.5	34
65	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2388-2397.	2.0	33
66	Natural Killer Cell Alloreactivity in Haploidentical Hematopoietic Stem Cell Transplantation. <i>International Journal of Hematology</i> , 2005, 81, 13-17.	0.7	32
67	The Effect of TNF- $\hat{\pm}$ on Regulatory T Cell Function in Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 356.	2.2	32
68	Immunotherapeutic Approaches for Hematologic Malignancies. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 337-353.	0.9	31
69	Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2005, 131, 483-486.	1.2	31
70	The Role of Megadose CD34+ Progenitor Cells in the Treatment of Leukemia Patients without a Matched Donor and in Tolerance Induction for Organ Transplantation. <i>Annals of the New York Academy of Sciences</i> , 1999, 872, 336-350.	1.8	30
71	Provision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 55-62.	0.6	28
72	Haploidentical transplant in patients with myelodysplastic syndrome. <i>Blood Advances</i> , 2017, 1, 1876-1883.	2.5	28

#	ARTICLE	IF	CITATIONS
73	The Evolution of T Cell Depleted Haploidentical Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2769.	2.2	28
74	Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. <i>Seminars in Immunopathology</i> , 2008, 30, 489-503.	2.8	27
75	Thymosin $\alpha 1$ to harness immunity to pathogens after haploidentical hematopoietic transplantation. <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 153-161.	1.8	27
76	Haploidentical Hematopoietic Stem Cell Transplantation With a Megadose T-Cell-Depleted Graft: Harnessing Natural and Adaptive Immunity. <i>Seminars in Oncology</i> , 2012, 39, 643-652.	0.8	25
77	CD44 signaling through p56lck involves lateral association with CD4 in human CD4+ T cells. <i>International Immunology</i> , 1999, 11, 1085-1092.	1.8	24
78	CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig. <i>Microbes and Infection</i> , 2005, 7, 1040-1048.	1.0	24
79	Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell-Dependent Graft-versus-Leukemia Effect in Murine Models. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1847-1851.	2.0	24
80	Isolation and characterization of Leu 7+ germinal-center cells with the T helper-cell phenotype and granular lymphocyte morphology. <i>Journal of Clinical Immunology</i> , 1986, 6, 205-215.	2.0	23
81	Opposing functions of activatory T-cell receptors and inhibitory NK-cell receptors on cytotoxic T cells. <i>Trends in Immunology</i> , 1996, 17, 450-453.	7.5	23
82	Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity. <i>European Journal of Immunology</i> , 1992, 22, 2047-2053.	1.6	22
83	Hematopoietic Stem Cell Transplantation from Alternative Donors for High-Risk Acute Leukemia: The Haploidentical Option. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 105-112.	0.6	21
84	Expansion of CD56-Negative, CD16-Positive, KIR-Expressing Natural Killer Cells after T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2011, 126, 13-20.	0.7	20
85	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. <i>Blood</i> , 2018, 132, 818-818.	0.6	19
86	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1900-1907.	1.3	18
87	Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans. <i>Frontiers in Immunology</i> , 2019, 10, 890.	2.2	16
88	Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2204-2210.	2.0	15
89	Haplo-BMT: which approach?. <i>Blood</i> , 2013, 121, 719-720.	0.6	14
90	CD4+FOXP3+ Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2901.	2.2	13

#	ARTICLE	IF	CITATIONS
91	Natural killer cells as a therapeutic tool in mismatched transplantation. Best Practice and Research in Clinical Haematology, 2004, 17, 427-438.	0.7	11
92	Identifying NK Alloreactive Donors for Haploidentical Hematopoietic Stem Cell Transplantation. Methods in Molecular Biology, 2016, 1393, 141-145.	0.4	11
93	T cell depletion and no post transplant immune suppression allow separation of graft versus leukemia from graft versus host disease. Bone Marrow Transplantation, 2019, 54, 775-779.	1.3	9
94	CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS.. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019048.	0.5	9
95	Tâ€œcellâ€œ depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT). Cancer, 2018, 124, 2142-2150.	2.0	8
96	TNFR2 signaling modulates immunity after allogeneic hematopoietic cell transplantation. Cytokine and Growth Factor Reviews, 2019, 47, 54-61.	3.2	8
97	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. Bone Marrow Transplantation, 2019, 54, 867-876.	1.3	8
98	Haploidentical Transplantation with Regulatory and Conventional T Cells Improves Outcome of Patients Affected By Acute Myeloid Leukemia with Complex Karyotype and/or Monosomy 7/Del(7q). Blood, 2018, 132, 2183-2183.	0.6	8
99	Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia. Frontiers in Immunology, 2021, 12, 695051.	2.2	7
100	Anti-KIR (1-7F9): A Fully Human Monoclonal Antibody (mAb) That Blocks KIR2DL1, âˆ² and âˆ³, Promoting Natural Killer (NK) Cell-Mediated Lysis of Tumor Cells In Vitro and In Vivo.. Blood, 2007, 110, 582-582.	0.6	7
101	ALLOGENEIC TRANSPLANTATION ACROSS THE HLA BARRIERS. Reviews in Clinical and Experimental Hematology, 2001, 5, 147-161.	0.1	6
102	Immunotherapy with alloreactive natural killer cells in haploidentical haematopoietic transplantation. The Hematology Journal, 2004, 5, S87-S90.	2.0	6
103	The Total Body Irradiation Schedule Affects Acute Leukemia Relapse After Matched T Cellâ€œDepleted Hematopoietic Stem Cell Transplantation. International Journal of Radiation Oncology Biology Physics, 2016, 96, 832-839.	0.4	6
104	Reduction in Incidence of Severe Infections by Transplantation of High Doses of Haploidentical T Cells Selectively Depleted of Alloreactive Units. Blood, 2011, 118, 3020-3020.	0.6	5
105	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters. Frontiers in Immunology, 2021, 12, 804988.	2.2	5
106	Progress in understanding and exploiting the immune response in solid organ and hemopoietic stem cell transplantation. Current Opinion in Immunology, 2009, 21, 522-524.	2.4	4
107	Differences in <i>Aspergillusâ€œ specific immune recovery between Tâ€œcellâ€œreplete and Tâ€œcellâ€œdepleted hematopoietic transplants. European Journal of Haematology, 2015, 95, 551-557.	1.1	4
108	The â€œultimateâ€œ haploidentical transplantation for the elderly with high-risk acute myeloid leukemia. Bone Marrow Transplantation, 2019, 54, 803-805.	1.3	4

#	ARTICLE	IF	CITATIONS
109	Rifaximin use favoured micafungin-resistant <i>Candida</i> spp. infections in recipients of allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 2375-2380.	0.8	4
110	How Adoptive Immunotherapy with Conventional T and Regulatory T Cells Exerts a GvL Effect without GvHD, after Haploidentical Hematopoietic Transplantation. <i>Blood</i> , 2018, 132, 3333-3333.	0.6	3
111	Total Marrow/Lymphoid Irradiation in the Conditioning Regimen for Haploidentical T-Cell-Depleted Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: The Perugia Experience. , 2020, , 111-121.		3
112	<i>In vivo</i> biological response following low-dose interleukin-2 in complete remission B-cell non-Hodgkin's lymphoma patients. <i>European Journal of Haematology</i> , 1996, 57, 33-37.	1.1	2
113	Natural revenge over cytomegalovirus. <i>Blood</i> , 2012, 119, 2438-2439.	0.6	2
114	Mother Donors Improve Outcomes after HLA Haploidentical Hematopoietic Transplantation: A Retrospective Study By the Cell Therapy and Immunobiology Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3472-3472.	0.6	2
115	Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients – study of Infectious Diseases Working Party of EBMT. <i>Journal of Infection</i> , 2021, , .	1.7	2
116	NK cell adoptive immunotherapy. <i>Blood</i> , 2005, 105, 3006-3006.	0.6	1
117	Natural killer cells and allogeneic haematopoietic cell transplantation. , 2010, , 543-553.		1
118	An Overview of Methods Required to Evaluate Donor NK Cell Alloreactivity for Haploidentical Haemopoietic Stem Cell Transplantation. <i>Methods in Molecular Biology</i> , 2012, 882, 469-476.	0.4	1
119	Thymosin Alfa 1 Administration Improves Immune Reconstitution and Decreases Infection-Related Mortality After HLA-Matched Sibling T Cell-Depleted Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1013-1013.	0.6	1
120	Adoptive Immunotherapy with Tregs and Tcons Ensures Low TRM and a Low Incidence of Post Transplant Leukaemia Relapse After HLA Haploidentical Transplants for Acute Leukemia. <i>Blood</i> , 2011, 118, 154-154.	0.6	1
121	Megadose of hematopoietic stem cells for haploidentical transplants. <i>Current Opinion in Organ Transplantation</i> , 2002, 7, 294-298.	0.8	0
122	Haploidentical Hematopoietic Stem Cell Transplantation: Step-by-Step Progress. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 579-580.	2.0	0
123	New mechanism of lymphoma-induced bone marrow aplasia. <i>Annals of Hematology</i> , 2016, 95, 1013-1015.	0.8	0
124	Haploidentical Transplants and NK Cell Alloreactivity. , 2018, , 145-157.		0
125	Donor Natural Killer Cell Allorecognition of Missing Self in Haploidentical Hematopoietic Transplantation for Acute Myeloid Leukemia: Challenging Its Predictive Value.. <i>Blood</i> , 2006, 108, 437-437.	0.6	0
126	Allogeneic Haematopoietic Stem Cell Transplantation and Natural Killer Cell Alloreactivity. , 2010, , 459-476.		0

#	ARTICLE	IF	CITATIONS
127	Deploying Natural Killer Cell Allotherapy in the Setting of HLA-Haplotype-Mismatched Hematopoietic Stem Cell Transplantation. , 2010, , 163-175.		0
128	Haploidentical Mismatched Allogeneic Versus Autologous Hematopoietic STEM CELL Transplantation in Adult Patients with ACUTE Myeloid Leukemia (AML) in First Complete Remission (CR1): A Pair-Matched Analysis From the Acute Leukemia Working Party of EBMT.. Blood, 2012, 120, 3093-3093.	0.6	0
129	HLA-Haploidentical Stem Cell Transplantation with Treg and Tcon Adoptive Immunotherapy promotes a Strong Graft-Versus-Leukemia Effect. Blood, 2013, 122, 907-907.	0.6	0
130	Safety and Immunogenicity Of Inactivated Varicella-Zoster Virus Vaccine In Adults With Hematologic Malignancies Receiving Treatment With Anti-CD20 Monoclonal Antibodies. Blood, 2013, 122, 2290-2290.	0.6	0
131	An Accelerated CD8+, but Not CD4+, T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT. Blood, 2015, 126, 1929-1929.	0.6	0
132	Alloreactive Natural Killer Cells Initiate a Unique Cellular and Molecular Pathway That Greatly Accelerates Immune Reconstitution after Allogeneic Bone Marrow Transplantation. Blood, 2016, 128, 548-548.	0.6	0
133	The Use of Monoclonal Antibody Directed Chimeric Antigen Receptors to Facilitate Conventional T Cell and Treg Control of GvHD and Tissue Tolerance in Murine Models. Blood, 2016, 128, 3355-3355.	0.6	0
134	Chemotherapy-Based HLA Haploidentical Transplantation with Treg/Tcon Immunotherapy in Unfit/Elderly Leukemia Patients: Powerful GvI Effect and Insights from Animal Models. Blood, 2016, 128, 3483-3483.	0.6	0
135	ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience. Blood, 2018, 132, 3381-3381.	0.6	0